'Cytokine storms' are a deadly problem in COVID-19. Researchers are testing promising solutions.
Some of the worst cases of COVID-19 involve patients who appear to get better then suddenly deteriorate, their lungs and other organs failing under an overwhelming immune response called a "cytokine storm." Cytokines are proteins sent out by a body's adaptive immune system — B and T cells — to recruit other immune cells to fight an infection. When the immune system doesn't shut off the cytokines, a storm of cells overwhelms organs, exhausting a body's immune response, causing dangerous inflammation, and attacking healthy tissues.
In COVID-19, scavenger cells called macrophages apparently attack and inflame the lungs, allowing liquid to fill air sacs and causing acute respiratory distress syndrome. An otherwise healthy woman in her 20s had a double lung transplant because COVID-19 irreparably destroyed her lungs, a Chicago hospital announced Thursday.
"It has become increasingly clear in the past few months that, at least in a subset of people who have the virus, calming the storm is the key to survival," The New York Times reports. Researchers are starting trials on several drugs to prevent or pacify cytokine storms, and others have reported some success with a dialysis-like device called CytoSorb that filters out cytokines from a patient's blood and returns it to the body.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
In China and Italy, doctors had some success with a drug called tocilizumab, marketed as Actemra by Roche, which blocks the cytokine interleukin-6 (IL-6). Another drug, Kineret, blocks a different cytokine, IL-1. A recent study published in the journal Science Immunology reported promising preliminary results from an AstraZeneca cancer drug called Calquence, or acalabrutinib, which aims to stop the cytokines at their root. Using a drug like tocilizumab is "like cutting the branches off a tree," Dr. Louis Staudt, a National Cancer Institute scientist and a lead investigator on the study, tells the Times. "Acalabrutinib is going for the trunk of the tree." AstraZeneca has plans to test the drug in larger trials.
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
'King's horses take free rein through London'
Today's Newspapers A roundup of the headlines from the US front pages
By The Week Staff Published
-
Is pop music now too reliant on gossip?
Talking Point Taylor Swift's new album has prompted a flurry of speculation over who she is referring to in her songs
By Richard Windsor, The Week UK Published
-
Nuclear near-misses
The Explainer From technical glitches to fateful split-second decisions, the world has come to the brink of nuclear war more times than you might think
By Rebecca Messina, The Week UK Published
-
Empty-nest boomers aren't selling their big homes
Speed Read Most Americans 60 and older do not intend to move, according to a recent survey
By Peter Weber, The Week US Published
-
Brazil accuses Musk of 'disinformation campaign'
Speed Read A Brazilian Supreme Court judge has opened an inquiry into Elon Musk and X
By Rafi Schwartz, The Week US Published
-
Disney board fends off Peltz infiltration bid
Speed Read Disney CEO Bob Iger has defeated activist investor Nelson Peltz in a contentious proxy battle
By Rafi Schwartz, The Week US Published
-
Disney and DeSantis reach detente
Speed Read The Florida governor and Disney settle a yearslong litigation over control of the tourism district
By Peter Weber, The Week US Published
-
Visa and Mastercard agree to lower swipe fees
Speed Read The companies will cap the fees they charge businesses when customers use their credit cards
By Peter Weber, The Week US Published
-
Reddit IPO values social media site at $6.4 billion
Speed Read The company makes its public debut on the New York Stock Exchange
By Peter Weber, The Week US Published
-
Housing costs: the root of US economic malaise?
speed read Many voters are troubled by the housing affordability crisis
By Peter Weber, The Week US Published
-
Feds cap credit card late fees at $8
speed read The Consumer Financial Protection Bureau finalized a rule to save households an estimated $10 billion a year
By Peter Weber, The Week US Published